+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Diabetic Neuropathy"

From
Nerve growth factor inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

Nerve growth factor inhibitors - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
From
From
From
Diabetic Neuropathy Market Report and Forecast 2023-2031 - Product Thumbnail Image

Diabetic Neuropathy Market Report and Forecast 2023-2031

  • Report
  • May 2023
  • 160 Pages
  • Global
From
Neuropathy Pain Treatment Market 2024-2028 - Product Thumbnail Image

Neuropathy Pain Treatment Market 2024-2028

  • Report
  • November 2023
  • 171 Pages
  • Global
From
Diabetic Neuropathy Drugs Market 2021-2025 - Product Thumbnail Image

Diabetic Neuropathy Drugs Market 2021-2025

  • Report
  • January 2022
  • 120 Pages
  • Global
From
From
From
From
From
Loading Indicator

Diabetic Neuropathy is a type of nerve damage caused by diabetes. It is a common complication of diabetes, affecting up to 70% of people with the condition. Symptoms of diabetic neuropathy can include pain, numbness, tingling, and loss of sensation in the feet, legs, and hands. It can also cause problems with balance and coordination, as well as digestive issues. Endocrinologists are medical professionals who specialize in the diagnosis and treatment of endocrine disorders, including diabetes. They are well-equipped to diagnose and treat diabetic neuropathy, as well as provide lifestyle advice to help manage the condition. Companies in the Diabetic Neuropathy market include Novartis, Sanofi, Eli Lilly, Merck, and Pfizer. Show Less Read more